Managers / Q1 2019 · view latest →
Healthcare Value Capital, LLC
CIK 0001458461 · 50 TICE BLVD, SUITE 140, WOODCLIFF LAKE, NJ, 07677 · 212-488-5411
Summary
Healthcare Value Capital, LLC reported $26M in U.S.-listed holdings across 10 positions for Q1 2019.
Its largest position, Allergan, represents 16.9% of the portfolio.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 67.0% · $17M
- Other · 33.0% · $9M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ALLERGAN PLC | NEW | +30.0K | 30.0K | +$4M | $4M |
| GLAXOSMITHKLINE PLC | NEW | +100.0K | 100.0K | +$4M | $4M |
| TYME TECHNOLOGIES INC | NEW | +2.17M | 2.17M | +$4M | $4M |
| VKTXVIKING THERAPEUTICS INC | NEW | +350.0K | 350.0K | +$3M | $3M |
| GILDGILEAD SCIENCES INC | NEW | +50.0K | 50.0K | +$3M | $3M |
| LGNDLIGAND PHARMACEUTICALS INC | NEW | +25.0K | 25.0K | +$3M | $3M |
| NOVELION THERAPEUTICS INC | NEW | +1.80M | 1.80M | +$2M | $2M |
| ANTARES PHARMA INC | NEW | +250.0K | 250.0K | +$758,000 | $758,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ALLERGAN PLC | SHS | 16.92% | $4M | 30.0K |
| 2 | GLAXOSMITHKLINE PLC | SPONSORED ADR | 16.10% | $4M | 100.0K |
| 3 | TYME TECHNOLOGIES INC | COM | 14.75% | $4M | 2.17M |
| 4 | GILDGILEAD SCIENCES INChistory → | COM | 12.53% | $3M | 50.0K |
| 5 | VKTXVIKING THERAPEUTICS INChistory → | COM | 9.57% | $2M | 250.0K |
| 6 | NOVELION THERAPEUTICS INC | COM NEW | 8.53% | $2M | 1.80M |
| 7 | ANTARES PHARMA INC | COM | 2.92% | $758,000 | 250.0K |
| 8 | ADAMAS PHARMACEUTICALS INC | COM | 2.74% | $711,000 | 100.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $51M | 25 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $50M | 23 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $45M | 22 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $30M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $30M | 18 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $39M | 19 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $59M | 26 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $34M | 16 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $55M | 22 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $53M | 19 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $26M | 10 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.